Beta Bionics, Inc. (BBNX) AI Stock Analysis

• Market Cap: $796.81M
• Dividend Yield: N/A
• Average Volume (3M): 665.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 97.91%
• EPS Growth: -34.11%
• Country: US
• Employees: 352
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Equipment & Services
• EPS (TTM): -0.39
• Shares Outstanding: 43,470,123
• 10 Day Avg. Volume: 707,454
• 30 Day Avg. Volume: 665,807
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 5.00
• Enterprise Value/Gross Profit: 9.26
• Enterprise Value/Ebitda: -5.89
• 1Y Price Target: $21.87
• Price Target Upside: 16.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 61 Neutral
• Price Target: $18.00 ▼(-3.79% Downside)

Beta Bionics, Inc. shows strong revenue growth and positive technical momentum, supported by promising product data. However, profitability challenges and valuation concerns weigh on the overall score. The optimistic earnings call and positive corporate events provide a favorable outlook, but financial performance remains a critical area for improvement.

Positive Factors

Commercial Strategy

BBNX's continued execution of its commercial strategy, particularly in pharmacy which continues to scale quicker than expected.

Pharmacy Channel

Management noted growth was driven by continued penetration of the pharmacy channel, broader PBM coverage, and continued strong uptake in MDI patients.

Negative Factors

Competitive Challenges

Fourth-to-market players can be tricky in med tech.

Market Share Risks

Risks include the inability to gain market share against larger players and potential delays to patch timing.

Beta Bionics, Inc. Business Overview & Revenue Model

Company Description

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

How the Company Makes Money

Beta Bionics makes money primarily through the sale of its bionic pancreas systems, including the iLet Bionic Pancreas. The company generates revenue from direct sales to healthcare providers, hospitals, and clinics, as well as through partnerships with diabetes care organizations and insurance providers. Additionally, Beta Bionics may leverage strategic partnerships with pharmaceutical companies or technology firms to enhance its product offerings and expand its market reach, thereby contributing to its revenue streams. The company may also earn income from ongoing customer support services and device maintenance contracts.

Beta Bionics, Inc. Financial Statement Overview

Summary

Beta Bionics, Inc. demonstrates impressive revenue growth but struggles with profitability and cash flow management. The balance sheet is stable with low leverage, but ongoing losses and negative cash flows pose risks.

Income Statement

Beta Bionics, Inc. shows strong revenue growth with a significant increase from previous years. However, the company is currently unprofitable, with negative EBIT, EBITDA, and net profit margins, indicating challenges in achieving operational efficiency and cost control.

Balance Sheet

The company's balance sheet reflects moderate leverage with a low debt-to-equity ratio and a healthy equity ratio, showcasing financial stability. However, the negative net income impacts the return on equity, which remains a concern for investors seeking profitability.

Cash Flow

Beta Bionics, Inc. faces challenges with negative free cash flow, indicative of high operational costs. Although there is a positive financing cash flow, indicating external funding, the operating cash flow to net income and free cash flow ratios are unfavorable, highlighting cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	78.02M	65.12M	11.99M	179.00K
Gross Profit	42.08M	35.89M	6.31M	179.00K
EBITDA	-66.16M	-44.10M	-34.62M	-63.40M
Net Income	-73.37M	-54.76M	-44.10M	-64.75M
Balance Sheet
Total Assets	329.97M	149.65M	110.04M	35.53M
Cash, Cash Equivalents and Short-Term Investments	249.72M	103.58M	96.75M	27.68M
Total Debt	6.69M	7.25M	4.22M	4.13M
Total Liabilities	28.34M	73.63M	51.43M	22.53M
Stockholders Equity	301.63M	76.01M	58.61M	13.00M
Cash Flow
Free Cash Flow	-62.05M	-51.67M	-32.85M	-60.98M
Operating Cash Flow	-57.46M	-48.27M	-32.45M	-60.21M
Investing Cash Flow	-187.37M	-3.48M	-69.69M	-769.00K
Financing Cash Flow	266.88M	55.62M	101.03M	56.78M

Beta Bionics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LH	76 Outperform	$23.14B	30.70	9.27%	1.05%	7.98%	72.22%
NVST	73 Outperform	$3.51B	67.77	1.76%	―	0.76%	―
BBNX	61 Neutral	$796.81M	―		―	97.91%	-34.11%
FTRE	55 Neutral	$815.38M	―	-100.49%	―	-4.96%	-284.00%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
TNDM	49 Neutral	$827.05M	―	-111.91%	―	25.84%	-47.67%
SANA	33 Underperform	$833.02M	―	-109.12%	―	―	7.58%

Beta Bionics, Inc. Corporate Events

Beta Bionics Unveils Promising iLet Bionic Pancreas Data

On June 22, 2025, Beta Bionics, Inc. presented updated real-world data on their iLet Bionic Pancreas at their first Investor and Analyst Event. The data, collected from over 16,000 users since the iLet’s commercial launch in May 2023, showed significant improvements in glucose management. Users experienced a reduction in average HbA1c levels from 8.9% to 7.3%, with over 84% meeting the American Diabetes Association’s hypoglycemia goals. This advancement positions Beta Bionics as a competitive player in the diabetes management industry, potentially enhancing stakeholder confidence and market presence.